A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Breast Cancer|Small-cell Lung Cancer|Pancreatic Cancer
Interventions: DRUG: SY-5609|DRUG: Fulvestrant|DRUG: Gemcitabine|DRUG: Nab-paclitaxel
Sponsor: Syros Pharmaceuticals